Merck to stop phase III LYNK-003 trial evaluating Lynparza with or without bevacizumab in metastatic colorectal cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Merck plans to stop the phase III LYNK-003 trial investigating Lynparza with or without bevacizumab for the treatment of patients with unresectable or metastatic colorectal cancer who have not progressed following first-line induction, citing futility. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login